Antibody-drug Conjugate Information

General Information of This Antibody-drug Conjugate (ADC)

ADC ID	DRG0PPHVA
ADC Name	Trastuzumab-SYNtansine
Synonyms	Trastuzumab-BCN-HydraSpace-vc-PABC-Ahx-maytansine Click to Show/Hide
Drug Status	Investigative
Indication	In total 1 Indication(s) Breast cancer [ICD11:2C60-2C65] Investigative
Drug-to-Antibody Ratio	3.7
Structure
	3D MOL	2D MOL
Antibody Name	Trastuzumab		Antibody Info
Antigen Name	Receptor tyrosine-protein kinase erbB-2 (ERBB2)		Antigen Info
Payload Name	Ahx-maytansine		Payload Info
Therapeutic Target	Microtubule (MT)		Target Info
Linker Name	BCN-HydraSpace-Val-Cit-PABC		Linker Info
Conjugate Type	GlycoConnect technology uses the globally conserved N-glycosylation site (Asn 279) to generate stable and site-specific ADCs based on enzymatic remodeling (engineered endoglycosidase and native glycosyl transferase).

General Information of The Activity Data Related to This ADC

Discovered Using Patient-derived Xenograft Model

Click To Hide/Show 2 Activity Data Related to This Level

Standard Type	Value	Units	Animal Model (No. of PDX)
Tumor Growth Inhibition value (TGI)	≈ 80.6	%	Breast cancer PDX model (PDX: T226)
Tumor Growth Inhibition value (TGI)	≈ 100	%	Breast cancer PDX model (PDX: T226)

Full List of Activity Data of This Antibody-drug Conjugate

Discovered Using Patient-derived Xenograft Model

Click To Hide/Show 2 Activity Data Related to This Level

Experiment 1 Reporting the Activity Date of This ADC				[1]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 80.60% (Day 23)	High HER2 expression (HER2+++)
Method Description	25 mice with T226 tumor (P12.1.4/0) between 75 and 196 mm³ were allocated, according to their tumor volume to give homogenous mean and median tumor volume in each treatment arm (5 mice/group). Treatments were initiated when the median tumor volume was 126 mm³ by intravenous injection with either vehicle (control), and trastuzumab-SYNtansine 3 mg/kg. Click to Show/Hide
In Vivo Model	Breast cancer PDX model (PDX: T226)
Experiment 2 Reporting the Activity Date of This ADC				[1]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 100.00% (Day 23)	High HER2 expression (HER2+++)
Method Description	25 mice with T226 tumor (P12.1.4/0) between 75 and 196 mm³ were allocated, according to their tumor volume to give homogenous mean and median tumor volume in each treatment arm (5 mice/group). Treatments were initiated when the median tumor volume was 126 mm³ by intravenous injection with either vehicle (control), and trastuzumab-SYNtansine 9 mg/kg. Click to Show/Hide
In Vivo Model	Breast cancer PDX model (PDX: T226)

References

Ref 1	Enzymatic glycan remodeling-metal free click (GlycoConnect) provides homogenous antibody-drug conjugates with improved stability and therapeutic index without sequence engineering. MAbs. 2022 Jan-Dec;14(1):2078466.